Ameriprise’s Neurogene NGNE Stock Holding History

Ameriprise’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-717	Closed	-$104K	–	4020
2021 Q3	$104K	Buy	717 +7	+1%	+$1.07K	﹤0.01%	3778
2021 Q2	$131K	Hold	710	–	–	﹤0.01%	3796
2021 Q1	$175K	Buy	+710	New	+$181K	﹤0.01%	3719

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise's NGNE Position: Q4 2021 in Review

Ameriprise sold out of Neurogene (NGNE) in Q4 2021, closing a stake of 717 shares — an estimated $104K sold.

Ameriprise first reported a position in NGNE in Q1 2021 and held it in 3 quarters. The position peaked at $175K in Q1 2021. 80 funds tracked by Wall St. Rank hold NGNE as of Q4 2021.

Ameriprise reported no remaining Neurogene position as of Q4 2021 after selling out during the quarter.
Ameriprise sold 717 Neurogene shares in Q4 2021, an estimated $104K.
Ameriprise first reported a position in Neurogene in Q1 2021 and held it in 3 quarters.
Ameriprise's Neurogene position peaked at $175K in Q1 2021.
80 funds tracked by Wall St. Rank held Neurogene as of Q4 2021.

Based on Ameriprise's 13F filing for Q4 2021, filed 14 Feb 2022.